Enovis Corporation (NYSE:ENOV) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Enovis Corporation (NYSE:ENOV) have been assigned an average recommendation of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $44.50.

A number of research analysts have recently commented on the company. Wall Street Zen lowered Enovis from a “buy” rating to a “hold” rating in a report on Sunday. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a report on Friday, April 10th. BTIG Research reissued a “buy” rating and set a $39.00 price target on shares of Enovis in a report on Friday, May 22nd. Evercore reissued an “outperform” rating and set a $36.00 price target on shares of Enovis in a report on Friday, May 8th. Finally, Wells Fargo & Company lowered their price target on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a report on Friday, May 8th.

Insider Activity at Enovis

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the stock in a transaction dated Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the completion of the acquisition, the insider owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders acquired 4,200 shares of company stock worth $92,084 over the last quarter. 2.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Arax Advisory Partners acquired a new position in shares of Enovis during the fourth quarter valued at $29,000. EverSource Wealth Advisors LLC boosted its stake in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares in the last quarter. GAMMA Investing LLC boosted its stake in Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after buying an additional 1,446 shares in the last quarter. Danske Bank A S bought a new position in Enovis during the third quarter valued at about $64,000. Finally, iSAM Funds UK Ltd bought a new position in Enovis during the third quarter valued at about $80,000. 98.45% of the stock is owned by institutional investors and hedge funds.

Enovis Price Performance

Shares of NYSE ENOV opened at $22.54 on Monday. Enovis has a 1-year low of $20.55 and a 1-year high of $36.82. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.05. The business’s fifty day moving average price is $23.58 and its two-hundred day moving average price is $24.04. The firm has a market capitalization of $1.30 billion, a PE ratio of -1.13 and a beta of 1.38.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The company had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, research analysts expect that Enovis will post 3.65 EPS for the current year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.